Clinical Trial Update: S-1 and and Gemcitabine vs Gemcitabine Alone as Adjuvant Chemotherapy for Patients With Resected Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating S-1 plus gemcitabine versus gemcitabine alone as adjuvant therapy after pancreatic cancer resection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• S-1 (tegafur/gimeracil/oteracil)

Snippet

Sponsor: Zhejiang University | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED